Identifying the child in need of asthma therapy.
Based on the results of the long-term CAMP clinical trial in childhood asthma, the benefits of continuous long-term use of inhaled glucocorticoid on asthma control are clear. Studies are in progress to evaluate whether early intervention with inhaled glucocorticoids can alter the natural history of asthma. Indicators are now being defined to identify the patient at risk for persistent asthma and thus to identify candidates for early intervention. Given the right medication and the patient profile, it may be possible to induce remission or even a cure. Patients with severe asthma have low pulmonary function that is difficult to improve, however. It will be important to recognize patients at risk for severe asthma and to intervene more effectively to prevent asthma progression. None of these advances will be possible without a comprehensive approach to asthma care including the ready access to health care. Although it seems that the rise in asthma mortality and morbidity has reached a plateau, there are significant racial and ethic disparities in asthma health care use and mortality. The goal should now be to strive for a reduction in asthma morbidity and mortality. A high proportion of asthma morbidity among inner-city children may be related to nonadherence; therefore targeting management approaches to improve adherence could prove effective in reducing morbidity. Recommendations have been made to integrate available resources in the United States to improve overall asthma outcomes for children.
Szefler
Stanley J
SJ
Department of Pediatrics, Division of Pediatric Clinical Pharmacology, National Jewish Medical and Research Center 1400 Jackson St., Room B121, Denver, CO 80206, USA. szeflers@njc.org
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D012307:Risk Factors
D018927:Anti-Asthmatic Agents